Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALZN NASDAQ:CDIO NASDAQ:GRTX NASDAQ:MBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALZNAlzamend Neuro$2.35+4.9%$3.01$2.06▼$135.54$6.82M-0.32217,296 shs110,055 shsCDIOCardio Diagnostics$3.45-10.9%$4.08$3.22▼$53.10$6.00M2.9641,957 shs72,559 shsGRTXGalera Therapeutics$0.02-3.4%$0.03$0.02▼$0.09$1.74M1.9190,851 shs8,219 shsMBIOMustang Bio$1.66+9.2%$1.64$0.89▼$21.95$7.27M2.22383,007 shs451,338 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALZNAlzamend Neuro0.00%+6.82%-26.56%-54.37%-87.77%CDIOCardio Diagnostics0.00%-11.08%-16.87%-26.89%-74.02%GRTXGalera Therapeutics0.00%0.00%-14.81%-2.54%-65.07%MBIOMustang Bio0.00%+12.93%-37.36%+46.90%-90.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALZNAlzamend Neuro2.9041 of 5 stars3.53.00.00.01.63.30.6CDIOCardio Diagnostics2.557 of 5 stars3.55.00.00.00.01.70.6GRTXGalera TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMBIOMustang Bio0.3172 of 5 stars0.02.00.00.02.40.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALZNAlzamend Neuro 3.00Buy$180.007,559.57% UpsideCDIOCardio Diagnostics 3.00Buy$60.001,639.13% UpsideGRTXGalera Therapeutics 0.00N/AN/AN/AMBIOMustang Bio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALZNAlzamend NeuroN/AN/AN/AN/A$4.95 per shareN/ACDIOCardio Diagnostics$40K150.08N/AN/A$7.10 per share0.49GRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/AMBIOMustang BioN/AN/AN/AN/A($2.11) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALZNAlzamend Neuro-$4.51MN/A0.00N/AN/AN/A-181.34%-116.84%9/10/2025 (Estimated)CDIOCardio Diagnostics-$8.38MN/A0.00∞N/A-28,539.39%-84.55%-74.63%8/11/2025 (Estimated)GRTXGalera Therapeutics-$59.08M-$0.26N/A∞N/AN/AN/A-99.34%8/12/2025 (Estimated)MBIOMustang Bio-$15.75M-$78.00N/AN/AN/AN/AN/A-31.30%8/12/2025 (Estimated)Latest GRTX, CDIO, ALZN, and MBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025N/ACDIOCardio Diagnostics-$1.80N/AN/AN/A$0.08 millionN/A8/8/2025Q2 2025MBIOMustang BioN/A-$0.19N/A-$0.19N/AN/A5/15/2025Q1 2025CDIOCardio Diagnostics-$0.06-$0.97-$0.91-$0.97$0.05 million$0.00 million5/14/2025Q1 2025MBIOMustang BioN/A-$0.05N/A-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALZNAlzamend NeuroN/AN/AN/AN/AN/ACDIOCardio DiagnosticsN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALZNAlzamend NeuroN/A6.586.58CDIOCardio DiagnosticsN/A19.4719.47GRTXGalera TherapeuticsN/A9.749.74MBIOMustang BioN/A1.341.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALZNAlzamend Neuro49.61%CDIOCardio Diagnostics8.06%GRTXGalera Therapeutics50.77%MBIOMustang Bio9.95%Insider OwnershipCompanyInsider OwnershipALZNAlzamend Neuro30.21%CDIOCardio Diagnostics22.30%GRTXGalera Therapeutics12.90%MBIOMustang Bio0.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALZNAlzamend Neuro42.90 million2.02 millionNo DataCDIOCardio Diagnostics11.74 million1.35 millionNot OptionableGRTXGalera Therapeutics3075.46 million47.38 millionOptionableMBIOMustang Bio1004.38 million4.37 millionNot OptionableGRTX, CDIO, ALZN, and MBIO HeadlinesRecent News About These CompaniesMustang Bio Inc.July 25, 2025 | barrons.comTalisker Receives Assay Results from 1105 Level Lateral Development at the Mustang MineJuly 24, 2025 | globenewswire.comMBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy - NasdaqJuly 10, 2025 | nasdaq.comMustang Bio Stock Jumps 180% After FDA Grants Orphan Drug Status to Brain Cancer DrugJuly 10, 2025 | msn.comBiotech Stock Mustang Bio, Inc. (Nasdaq: MBIO) Soars on Orphan Drug Designation by U.S. FDAJuly 9, 2025 | investorideas.comIMustang Bio Inc News (MBIO) - Investing.comJuly 9, 2025 | investing.comMBIO Soars on Orphan Drug Nod for Investigational Brain Cancer TherapyJuly 8, 2025 | zacks.comDow Dips 1%; Mustang Bio Shares Spike HigherJuly 7, 2025 | benzinga.comThis BlackRock stock just spiked over 300%July 7, 2025 | finbold.comFMustang Bio stock soars after FDA grants orphan drug designationJuly 7, 2025 | investing.comMustang Bio rises after FDA orphan drug status for MB-101July 7, 2025 | msn.comMustang Bio Shares Surge After FDA Grants Orphan Drug StatusJuly 7, 2025 | msn.comMustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and GlioblastomaJuly 7, 2025 | globenewswire.comMustang Bio, Inc. (MBIO) - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comMustang Bio treatment of malignant glioma granted orphan designationJuly 2, 2025 | msn.comMBIO Mustang Bio, Inc. - Seeking AlphaJune 25, 2025 | seekingalpha.comMustang Bio’s first-of-a-kind CAR-T starts trialsMay 1, 2025 | pharmaphorum.comPMustang Bio meets Nasdaq’s equity listing requirementsMarch 7, 2025 | investing.comMustang Bio Regains Nasdaq Compliance, Secures Position For Cell Therapy AdvancementsMarch 7, 2025 | nasdaq.comMustang Bio regains compliance with Nasdaq requirementMarch 5, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRTX, CDIO, ALZN, and MBIO Company DescriptionsAlzamend Neuro NASDAQ:ALZN$2.35 +0.11 (+4.91%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$2.37 +0.02 (+0.85%) As of 08/8/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.Cardio Diagnostics NASDAQ:CDIO$3.46 -0.41 (-10.57%) As of 08/8/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.Galera Therapeutics NASDAQ:GRTX$0.02 0.00 (-3.36%) As of 08/8/2025 01:59 PM EasternGalera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.Mustang Bio NASDAQ:MBIO$1.66 +0.14 (+9.21%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.62 -0.04 (-2.71%) As of 08/8/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access Sale